Altamira Therapeutics Ltd. Actuarial Gains Losses Arising From Experience Adjustments Net Defined Benefit Liability Asset
Altamira Therapeutics Ltd. (CYTOF) reported Actuarial Gains Losses Arising From Experience Adjustments Net Defined Benefit Liability Asset of -$16.75 thousand for the 12-month period ending 2024-12-31, per its 20-F filed 2025-04-30.
Financial Statements › Income Statement › Other Income
ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset · last filed 2025-04-30
CHF
| Period end | Actuarial Gains Losses Arising From Experience Adjustments Net Defined Benefit Liability Asset 12 month | Actuarial Gains Losses Arising From Experience Adjustments Net Defined Benefit Liability Asset 12 month as first filed |
|---|---|---|
| 2023-12-31 | -138.50K CHF 20-F/A · filed 2024-04-22 | |
| 2022-12-31 | -54.80K CHF 20-F/A · filed 2024-04-22 | |
| 2021-12-31 | 463.24K CHF 20-F/A · filed 2024-04-22 | |
| 2020-12-31 | 45.88K CHF 20-F · filed 2023-05-16 | |
| 2019-12-31 | -215.16K CHF 20-F · filed 2022-04-12 | |
| 2018-12-31 | -1.79M CHF 20-F · filed 2021-03-31 | 1.79M CHF 20-F · filed 2019-03-14 |
| 2017-12-31 | 211.33K CHF 20-F · filed 2020-04-16 | -211.33K CHF 20-F · filed 2018-03-22 |
| 2016-12-31 | -264.42K CHF 20-F · filed 2019-03-14 | |
| 2015-12-31 | -175.38K CHF 20-F · filed 2018-03-22 |
USD
| Period end | Actuarial Gains Losses Arising From Experience Adjustments Net Defined Benefit Liability Asset 12 month |
|---|---|
| 2024-12-31 | -$16.75K 20-F · filed 2025-04-30 |
| 2023-12-31 | $154.14K 20-F · filed 2025-04-30 |
| 2022-12-31 | $57.38K 20-F · filed 2025-04-30 |